167 related articles for article (PubMed ID: 37496220)
21. [Research progress on neoadjuvant immunotherapy for locally advanced head and neck squamous cell carcinoma].
Song YX; Gui L; Liu SY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Feb; 59(2):187-191. PubMed ID: 38310370
[TBL] [Abstract][Full Text] [Related]
22. Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Yalamanchali A; Yang K; Roof L; Lopetegui-Lia N; Schwartzman LM; Campbell SR; Woody NM; Silver N; Koyfman S; Geiger JL; Yilmaz E
Head Neck; 2023 Apr; 45(4):862-871. PubMed ID: 36806299
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
Specenier P
Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy.
Jiang C; Zhou X; Han J; Yue Z; Li B
Oncologist; 2022 Jul; 27(7):e604-e605. PubMed ID: 35536754
[TBL] [Abstract][Full Text] [Related]
25. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
26. The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck.
Misiukiewicz K; Camille N; Gupta V; Bakst R; Teng M; Miles B; Genden E; Sikora A; Posner M
Clin Adv Hematol Oncol; 2014 Dec; 12(12):812-9. PubMed ID: 25674839
[TBL] [Abstract][Full Text] [Related]
27. [Immunotherapy for head and neck squamous cell carcinoma].
Chen J; Chen M; Wu HT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
[TBL] [Abstract][Full Text] [Related]
28. Using routine data to estimate survival and recurrence in head and neck cancer: our preliminary experience in twenty patients.
Liu ZW; Fitzke H; Williams M
Clin Otolaryngol; 2013 Aug; 38(4):334-9. PubMed ID: 23621396
[No Abstract] [Full Text] [Related]
29. Immunotherapeutic Strategies for Head and Neck Cancer.
Buchwald ZS; Schmitt NC
Otolaryngol Clin North Am; 2021 Aug; 54(4):729-742. PubMed ID: 34116846
[TBL] [Abstract][Full Text] [Related]
30. Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report.
Zhou J; Luo J; Gu J; Zhang J; Gu D; Zhang X; Wang F; He X; Wu L
Medicine (Baltimore); 2023 Aug; 102(31):e33797. PubMed ID: 37543761
[TBL] [Abstract][Full Text] [Related]
31. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Yu Y; Lee NY
Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
[TBL] [Abstract][Full Text] [Related]
32. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: application of high b-value diffusion-weighted imaging.
Hwang I; Choi SH; Kim YJ; Kim KG; Lee AL; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2013 Dec; 34(12):2343-8. PubMed ID: 23811978
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Head and Neck Cancer.
Trivedi S; Sun L; Aggarwal C
Hematol Oncol Clin North Am; 2021 Oct; 35(5):1021-1037. PubMed ID: 34244017
[TBL] [Abstract][Full Text] [Related]
35. Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Saba NF; Mendenhall WM; Hutcheson K; Suárez C; Wolf G; Ferlito A
Cancer; 2018 Nov; 124(21):4163-4164. PubMed ID: 30289965
[No Abstract] [Full Text] [Related]
36. Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma.
Deeken JF; Newkirk K; Harter KW; Marshall MB; Banovac F; Johnson L; Wang H; Wang Y; Zhuang T; Jay AK; Berkowitz F; Esposito G; Kallakury B; Davidson B
Head Neck; 2015 May; 37(5):630-5. PubMed ID: 24616038
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis.
De Felice F; Bossi P
Oral Oncol; 2023 Feb; 137():106275. PubMed ID: 36542994
[No Abstract] [Full Text] [Related]
38. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):85-100. PubMed ID: 30449528
[TBL] [Abstract][Full Text] [Related]
39. [Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck : highlights of the ASCO Meeting 2013].
Hezel M; Kurzweg T; Münscher A; Schafhausen P; Knecht R
HNO; 2013 Nov; 61(11):911-3. PubMed ID: 24221219
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
